346729-61-1

Basic information

• Product Name: 4-Piperidinol, 4-[4-chloro-3-(trifluoromethyl)phenyl]-1-(phenylmethyl)-
• CAS NO: 346729-61-1
• Molecular Formula: C19H19ClF3NO
• Molecular Weight: 369.814
• Mol File: 346729-61-1.mol
• Article Data: 4

Chemical Properties

• CAS DataBase Reference: 4-Piperidinol, 4-[4-chloro-3-(trifluoromethyl)phenyl]-1-(phenylmethyl)-(CAS DataBase Reference)
• NIST Chemistry Reference: 4-Piperidinol, 4-[4-chloro-3-(trifluoromethyl)phenyl]-1-(phenylmethyl)-(346729-61-1)
• EPA Substance Registry System: 4-Piperidinol, 4-[4-chloro-3-(trifluoromethyl)phenyl]-1-(phenylmethyl)-(346729-61-1)

Safety Data

• Hazardous Substances Data: 346729-61-1(Hazardous Substances Data)

Upstream product

• 21928-50-7 4-[4-chloro-3-trifluoromethylphenyl]-4-piperidinol 
• 100-39-0 benzyl bromide 
• 445-01-2 5-bromo-2-chlorobenzotrifluoride 
• 3612-20-2 1-phenylmethyl-4-piperidone 

Relevant articles and documents

Structure-Based Design and Synthesis of Piperidinol-Containing Molecules as New Mycobacterium abscessus Inhibitors

Non-tuberculous mycobacterium (NTM) infections, such as those caused by Mycobacterium abscessus, are increasing globally. Due to their intrinsic drug resistance, M. abscessus pulmonary infections are often difficult to cure using standard chemotherapy. We previously demonstrated that a piperidinol derivative, named PIPD1, is an efficient molecule both against M. abscessus and Mycobacterium tuberculosis, the agent of tuberculosis, by targeting the mycolic acid transporter MmpL3. These results prompted us to design and synthesize a series of piperidinol derivatives and to determine the biological activity against M. abscessus. Structure-activity relationship (SAR) studies pointed toward specific sites on the scaffold that can tolerate slight modifications. Overall, these results identified FMD-88 as a new promising active analogue against M. abscessus. Also, we determined the pharmacokinetics properties of PIPD1 and showed that intraperitoneal administration of this compound resulted in promising serum concentration and an elimination half-life of 3.2 hours.

Piperazinylacylpiperidine derivatives, their preparation and therapeutic use thereof

The invention relates to substituted 1-piperazinylacylpiperidine derivatives of general formula (I) in which: n is 1 or 2; p is 1 or 2; R1 represents a halogen atom; a trifluoromethyl radical; a (C1-C4)alkyl; a (C1-C4)alkoxy; a trifluoromethoxy radical; R2 represents a hydrogen atom or a halogen atom; R3 represents a hydrogen atom; a group —OR5; a group —CH2OR5; a group —NR6R7; a group —NR8COR9; a group —NR8CONR10R11; a group —CH2NR12R13; a group —CH2NR8CONR14R15; a (C1-C4)alkoxycarbonyl; a group —CONR16R17; or else R3 constitutes a double bond between the carbon atom to which it is attached and the adjacent carbon atom of the piperidine ring; R4 represents an aromatic group selected from: the said aromatic groups being unsubstituted or being mono- or disubstituted by a substituent selected independently from a halogen atom; a (C1-C4)alkyl; a (C1-C4)alkoxy; a trifluoromethyl radical; Preparation process and therapeutic application.